{"preliminary_commentary":{"by_channel":{"x_thread":18,"youtube":4,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02927769\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"CheckMate 744","nct_id":"NCT02927769","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-744-nct02927769. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CheckMate 744","arms":[{"description":null,"label":"Nivolumab + brentuximab vedotin","type":"EXPERIMENTAL"},{"description":null,"label":"brentuximab vedotin + bendamustine","type":"EXPERIMENTAL"}],"collaborators":["Seagen Inc."],"completion_date":{"date":"2024-05-28","type":"ACTUAL"},"conditions":["Hodgkin Disease"],"enrollment":{"count":72,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","otherNames":["BMS-936558","Opdivo"],"type":"BIOLOGICAL"},{"name":"brentuximab vedotin","otherNames":[],"type":"BIOLOGICAL"},{"name":"bendamustine","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2025-02-10","lead_sponsor":"Bristol-Myers Squibb","official_title":"Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-05-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1","timeFrame":"From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks)."},{"measure":"Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1","timeFrame":"At 3 years post first dose of study therapy"},{"measure":"Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2","timeFrame":"From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks)"}],"references":[{"citation":"Daw S, Cole PD, Hoppe BS, Hodgson D, Beishuizen A, Garnier N, Buffardi S, Mascarin M, Lissat A, Mauz-Korholz C, Krajewski J, Akyol A, Crowe R, Anderson B, Xu Y, Drachtman RA, Kelly KM, Leblanc T, Harker-Murray P. Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults: A Nonrandomized Clinical Trial. JAMA Oncol. 2025 Mar 1;11(3):249-257. doi: 10.1001/jamaoncol.2024.5627.","pmid":"39745739","type":"DERIVED"},{"citation":"Harker-Murray P, Mauz-Korholz C, Leblanc T, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger KJ, Amoroso L, Buffardi S, Rigaud C, Hoppe BS, Lisano J, Francis S, Sacchi M, Cole PD, Drachtman RA, Kelly KM, Daw S. Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. Blood. 2023 Apr 27;141(17):2075-2084. doi: 10.1182/blood.2022017118.","pmid":"36564047","type":"DERIVED"}],"start_date":{"date":"2017-03-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment","url":"https://clinicaltrials.gov/study/NCT02927769"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-744-nct02927769"}